Axsome Therapeutics, Inc. (AXSM) FinancialsAXSMAxsome Therapeutics, Inc.

Axsome Therapeutics, Inc. (AXSM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is SUNOSI milestone revenue, accounting for 100.2% of total sales, equivalent to $218.92M. Other significant revenue streams include Auvelitv and Sunosi. Understanding this composition is critical for investors evaluating how AXSM navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Axsome Therapeutics, Inc. maintains a gross margin of 93.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23.42%, while the net margin is -23.50%. These profitability ratios, combined with a Return on Equity (ROE) of -245.10%, provide a clear picture of how effectively AXSM converts its operational activities into shareholder value.

In the context of the broader market, AXSM competes directly with industry leaders such as ARWR and IOVA. With a market capitalization of $7.55B, it holds a significant position in the sector. When comparing efficiency, AXSM's gross margin of 93.06% stands against ARWR's 100.00% and IOVA's 46.54%. Such benchmarking helps identify whether Axsome Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Axsome Therapeutics reported a total revenue of $218.4 million in Q2 2026, a 46% increase year-over-year, but continues to face net losses, with a reported loss per share of -0.99.